Diabetic ketoacidosis induced by liraglutide overdose for weight loss in a type 2 diabetes patient: A case report.
Medicine (Baltimore) · 2026
Last updated 2026-05-28A 43-year-old woman with type 2 diabetes took 10 times the recommended dose of liraglutide (18 mg over 3 days) for weight loss, leading to severe diabetic ketoacidosis (DKA) with a blood pH of 6.9. Standard treatments failed to correct the life-threatening condition, but hemodialysis quickly stabilized her. The case highlights the risks of misusing liraglutide and the need for strict adherence to prescribed doses.
AI summary of the abstract below.
| Journal | Medicine (Baltimore), 2026 |
|---|---|
| Citations | 0 |
| Molecules | liraglutide |
| Conditions studied | Type 2 Diabetes, Obesity |
Abstract
BACKGROUND: Type 2 diabetes mellitus is a major global health concern. Liraglutide, a glucagon-like peptide-1 receptor agonist, is widely used for glycemic control and weight loss. While generally safe, its misuse, particularly overdose, poses severe risks that are poorly documented. This case report aims to describe the clinical course and management of a life-threatening diabetic ketoacidosis (DKA) induced by a massive liraglutide overdose, highlighting the critical importance of patient education and adherence to prescribing guidelines.
METHODS: We present a case report of a 43-year-old female with type 2 diabetes mellitus who self-administered liraglutide at 10 times the recommended dose (cumulative 18 mg over 3 days).
RESULTS: Following the overdose, the patient was diagnosed with severe DKA (pH 6.9), with markedly elevated β-hydroxybutyrate and hyperkalemia. Conventional management failed to correct the life-threatening acidosis, necessitating salvage hemodialysis, which rapidly stabilized her metabolic parameters.
CONCLUSION: This case underscores the dangers of liraglutide overdose, particularly for weight loss purposes, and highlights the critical need for strict adherence to prescribed dosages and comprehensive patient education. Clinicians should vigilantly monitor liraglutide therapy to prevent severe complications like DKA. In refractory DKA with profound acidosis (pH ≤ 7.0) or end-organ compromise, hemodialysis may be considered for rapid detoxification and stabilization. This report serves as a critical reminder of the potential dangers associated with glucagon-like peptide-1 receptor agonist misuse.
Verbatim abstract via PubMed 41578502 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.